secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-05-14T11:05:16+00:00
Accession:  0001193125-26-222750
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint receives third positive DSMC recommendation for Phase 3 wet AMD DURAVYU trials
--------------------------------------------------------------------------------

- DSMC recommends LUGANO and LUCIA continue without modification; all active treatment-arm patients have received second DURAVYU dose.
- Over 35% of patients have received third planned dose at Week 56; safety profile consistent with >190 patients across prior trials.
- Topline data from LUGANO expected mid-2026; LUCIA readout to follow shortly after.
- Trials enroll over 900 patients; primary endpoint is non-inferiority in mean BCVA change at weeks 52 and 56.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/0001193125-26-222750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer